Investors

Targeted Therapeutics for Cancer and Ophthalmology

Investors
Webcast ImageWebcast
TRACON Pharmaceuticals Inc at 28th Annual Piper Jaffray Healthcare Conference (Replay)
11/30/16 at 9:30 a.m. ET
TRACON Pharmaceuticals Inc at 28th Annual Piper Jaffray Healthcare Conference
Wednesday, November 30, 2016 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
TRACON Pharmaceuticals Inc - Key Opinion Leader Meeting (Replay)
12/01/16 at 12:00 p.m. ET
TRACON Pharmaceuticals Inc - Key Opinion Leader Meeting
Thursday, December 1, 2016 12:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. Each of our product candidates is expected to complement currently available therapies.
Stock Quote
TCON (Common Stock)
Exchange:NASDAQ CM
Volume:0
$5.750.00 (0.00%)
Data as of 12/02/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
November 29, 2016
TRACON Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
November 23, 2016
TRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock
November 22, 2016
TRACON Pharmaceuticals to Host Key Opinion Leader Luncheon for Investors Focused on Angiosarcoma and Prostate Cancer on December 1 in New York City
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever TRACON Pharmaceuticals Inc posts new information to the site. Just enter your email address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
 
Print Page |
 
Email Page |
 
RSS Feeds |
 
Email Alerts |
 
Contact IR